

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF CR DOUBLE-CRANE FOR THE YEAR ENDED 31 DECEMBER 2017

On 14 March 2018, CR Double-Crane released its annual report for the year ended 31 December 2017.

China Resources Double-Crane Pharmaceutical Company Limited (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”) is a company incorporated in the People’s Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 59.99% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 14 March 2018, CR Double-Crane released its annual report for the year ended 31 December 2017 (the “**CR Double-Crane Audited Annual Financials**”). Set out below is the key financial information of the CR Double-Crane Audited Annual Financials:

	As of 31 December 2017 <i>(RMB)</i> (audited)	As of 31 December 2016 <i>(RMB)</i> (audited)	Increase/decrease <i>(%)</i>
Total assets	9,437,896,362.60	8,241,549,950.56	14.52%
Net assets attributable to shareholders of the listed company	7,456,791,301.52	6,686,214,420.11	11.52%
	For the year ended		
	31 December 2017 <i>(RMB)</i> (audited)	31 December 2016 <i>(RMB)</i> (audited)	Increase/decrease <i>(%)</i>
Revenue	6,421,846,768.78	5,494,803,869.14	16.87%
Net profit attributable to the shareholders of the listed company	842,612,497.04	714,210,861.10	17.98%
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	816,219,678.74	657,776,316.70	24.09%
Net cash flow from operating activities	1,187,087,990.93	771,247,822.97	53.92%
Basic earnings per share <i>(RMB/share)</i>	0.9692	0.8215	17.98%
Diluted earnings per share <i>(RMB/share)</i>	0.9692	0.8215	17.98%
Weighted average return on net asset	11.91%	11.15%	0.76 percentage points

As determined by the board of directors of CR Double-Crane, CR Double-Crane proposed to distribute a cash dividend of RMB0.97 (inclusive of tax) for every 10 shares and 2 bonus shares for every 10 shares (inclusive of tax) to all shareholders of CR Double-Crane based on the aggregate share capital of 869,364,758 shares as of 31 December 2017. Such proposal shall be submitted for shareholders’ approval at CR Double-Crane’s 2017 annual general meeting.

The CR Double-Crane Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Audited Annual Financials, please refer to the annual report for the year ended 31 December 2017 published by CR Double-Crane on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Beijing, the PRC, 15 March 2018

As of the date of this announcement, the Board of Directors of the Company comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.